Free shipping on all orders over $ 500
Ubrogepant (MK-1602) is a novel oral calcitonin gene-associated peptide receptor (CGRP) antagonist with the potential to be used in acute migraine studies.
| Molecular Weight | 549.54 |
| Formula | C29H26F3N5O3 |
| CAS Number | 1374248-77-7 |
| Solubility (25°C) | DMSO ≥ 200 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] No authors listed. Expert Opin Pharmacother. Ubrogepant
[2] No authors listed. Expert Opin Pharmacother. Ubrogepant
[3] Martina Curto, et al. Expert Opin Pharmacother. Ubrogepant for the treatment of migraine
[4] David W Dodick, et al. N Engl J Med. Ubrogepant for the Treatment of Migraine
| Related CGRP Receptor Products |
|---|
| α-CGRP, human TFA
α-CGRP, human TFA is a regulatory neuropeptide of 37 amino acids. α-CGRP, human TFA can be used as a potent vasodilator. |
| Fremanezumab
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research. |
| Eptinezumab
Eptinezumab is a human monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. Eptinezumab can be used for the prevention of migraine in adults. |
| Erenumab
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine. |
| Galcanezumab
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
